FI3191120T3 - Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla - Google Patents

Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla Download PDF

Info

Publication number
FI3191120T3
FI3191120T3 FIEP15767597.6T FI15767597T FI3191120T3 FI 3191120 T3 FI3191120 T3 FI 3191120T3 FI 15767597 T FI15767597 T FI 15767597T FI 3191120 T3 FI3191120 T3 FI 3191120T3
Authority
FI
Finland
Prior art keywords
secukinumab
use according
progression
acid derivative
structural damage
Prior art date
Application number
FIEP15767597.6T
Other languages
English (en)
Finnish (fi)
Inventor
Shephard Mpofu
Hanno Richards
Gregory Ligozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3191120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3191120T3 publication Critical patent/FI3191120T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
FIEP15767597.6T 2014-09-10 2015-09-08 Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla FI3191120T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
FI3191120T3 true FI3191120T3 (fi) 2024-07-10

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15767597.6T FI3191120T3 (fi) 2014-09-10 2015-09-08 Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla

Country Status (22)

Country Link
US (2) US11278618B2 (enExample)
EP (2) EP3191120B1 (enExample)
JP (4) JP2017528465A (enExample)
KR (2) KR20230170796A (enExample)
CN (4) CN115957326A (enExample)
AU (2) AU2015313827C1 (enExample)
BR (1) BR112017003332A2 (enExample)
CA (1) CA2960754A1 (enExample)
DK (1) DK3191120T3 (enExample)
ES (1) ES2981697T3 (enExample)
FI (1) FI3191120T3 (enExample)
HR (1) HRP20240921T1 (enExample)
HU (1) HUE067081T2 (enExample)
LT (1) LT3191120T (enExample)
MX (1) MX2017003216A (enExample)
PL (1) PL3191120T3 (enExample)
PT (1) PT3191120T (enExample)
RS (1) RS65851B1 (enExample)
RU (1) RU2697383C2 (enExample)
SI (1) SI3191120T1 (enExample)
SM (1) SMT202400285T1 (enExample)
WO (1) WO2016038538A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115957326A (zh) 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
US20210179702A1 (en) * 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
MA56124A (fr) * 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
CN115957326A (zh) * 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展

Also Published As

Publication number Publication date
JP2023109973A (ja) 2023-08-08
US11278618B2 (en) 2022-03-22
AU2015313827C1 (en) 2018-08-30
EP4406969A2 (en) 2024-07-31
EP4406969A3 (en) 2024-11-27
RS65851B1 (sr) 2024-09-30
AU2015313827B2 (en) 2018-02-15
CN113069542A (zh) 2021-07-06
US20170281762A1 (en) 2017-10-05
SI3191120T1 (sl) 2024-10-30
MX2017003216A (es) 2017-05-23
HRP20240921T1 (hr) 2024-10-11
LT3191120T (lt) 2024-07-25
PT3191120T (pt) 2024-07-16
EP3191120B1 (en) 2024-04-10
KR20230170796A (ko) 2023-12-19
DK3191120T3 (da) 2024-07-15
CN115957326A (zh) 2023-04-14
EP3191120A1 (en) 2017-07-19
AU2015313827A1 (en) 2017-02-16
RU2017107501A (ru) 2018-10-10
RU2697383C2 (ru) 2019-08-13
JP2017528465A (ja) 2017-09-28
JP2025024104A (ja) 2025-02-19
ES2981697T3 (es) 2024-10-10
JP2021152021A (ja) 2021-09-30
SMT202400285T1 (it) 2024-09-16
BR112017003332A2 (pt) 2017-11-28
JP7288927B2 (ja) 2023-06-08
CA2960754A1 (en) 2016-03-17
RU2017107501A3 (enExample) 2019-03-12
CN107073110A (zh) 2017-08-18
PL3191120T3 (pl) 2024-08-26
CN115944734A (zh) 2023-04-11
HUE067081T2 (hu) 2024-09-28
WO2016038538A1 (en) 2016-03-17
AU2018201410A1 (en) 2018-03-22
US20220313818A1 (en) 2022-10-06
JP7591092B2 (ja) 2024-11-27
KR20170045240A (ko) 2017-04-26

Similar Documents

Publication Publication Date Title
FI3191120T3 (fi) Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
NZ601529A (en) Tapentadol compositions
EP2734500A4 (en) SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
IL300130B1 (en) Novel combinations for antigen based therapy
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
JP2019532634A5 (enExample)
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
HRP20260324T1 (hr) Guselkumab za upotrebu u liječenju crohnove bolesti uz režim doziranja
FR2956313B1 (fr) Appareil pour l'administration d'une substance visqueuse pendant une operation chirurgicale.
EP3177357C0 (fr) Dispositif pour l'introduction d'une canule à bout arrondi sous la peau d'un patient et kit
RU2016148183A (ru) (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине
RU2018126158A (ru) Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени
CR20150646A (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa
JP2016520556A5 (enExample)
RU2016148182A (ru) (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
AR063228A1 (es) Antinflamatorios no esteroideos contra la tos
EP4054698C0 (en) DISPOSABLE CARTRIDGE AND PUMP TRACK MECHANISM
AR101860A1 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
HUE060169T2 (hu) Többrétegû szerkezetû pelletek egy gyógyszer késleltetett leadására a disztális bélben
EP2448573A4 (en) MEDICAMENT FOR LONG-TERM NSAID USE
EA201890122A1 (ru) Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог
BR112015016304A8 (pt) formulações de liberação prolongada de lorazepam
RU2016106521A (ru) Способ обезболивания в стоматологии